Form 4: Kymera Therapeutics Director Acquires Stock Options

Kymera Therapeutics Director Victor Sandor acquired stock options for 6,068 shares of common stock on June 24, 2026.

Summary

• Victor Sandor, a Director at Kymera Therapeutics, Inc., was granted stock options on June 24, 2026.
• The options are for 6,068 shares of common stock with an exercise price of $99.87 per share.
• These options are exercisable on June 23, 2036.
• The underlying shares are subject to vesting conditions: full vesting occurs on June 24, 2027, or the next annual stockholder meeting, whichever comes first.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock option grant to a director, which is a common compensation mechanism and does not inherently signal significant positive or negative news.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The grant of options aligns the director's interests with those of shareholders.

Future Outlook

The vesting schedule for the stock options suggests a medium-term outlook for the director's continued engagement and potential benefit from the company's performance.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with long-term shareholder value creation.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns their interests with shareholders, potentially encouraging actions that benefit the company's stock price.

Key Dates

Keywords

Kymera Therapeutics, KYMR, Form 4, Stock Options, Director, Beneficial Ownership, Securities Exchange Act